ReviewAntonie van Leeuwenhoek2026
Lactose intolerance and probiotics: from pathophysiological mechanisms to clinical applications.
Review in Antonie van Leeuwenhoek, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Robustness-by-design for Probiotic Foods: Mechanisms, Non-thermal Stress Conditioning, and Engineered Microenvironments.Probiotics and antimicrobial proteins · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactose is a disaccharide found in dairy products, which provide energy and essential nutrients. Digestion of lactose relies on the intestinal enzyme lactase, or lactase-phlorizin hydrolase, located on the brush border of the small bowel mucosa. This enzyme splits lactose into two absorbable monosaccharides: glucose and galactose. When lactase activity is insufficient, undigested lactose proceeds to the colon where it is fermented by the gut flora, generating gas that trigger the uncomfortable symptoms associated with lactose intolerance. Lactase non-persistence is extremely common, affecting approximately 70% of the adult population world-wide. Prevalence varies markedly across geographic regions, typically ranging from 50 to 90% in African, Asian, and South American countries. The subjective diagnosis of lactose intolerance requires the occurrence of symptoms such as abdominal pain, bloating, flatulence and diarrhea following the ingestion of high lactose dairy products. An objective assessment of lactose intolerance may be achieved with a specific breath test that measures hydrogen emission in breath following the ingestion of lactose. Consequently, current international guidelines require concurrent report of typical symptoms and pathologic breath test results in order to diagnose lactose intolerance. Management of lactose intolerance often involves dietary restrictions and the prescription of formulations that contain lactase. However, one should recognize that avoiding dairy products can increase the risk of nutritional deficiencies. Therefore, ongoing research is focused on alternative strategies, notably utilizing gut microbiota in order to improve tolerance to lactose. This review aims to explore the evidence supporting the use of probiotics as a potential treatment strategy to alleviate the symptoms of lactose intolerance by modulating colonic metabolism and enhancing lactose digestion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.